Acetylsalicylsäure – von der kardiovaskulären zur Karzinomprävention

 

 Buy Article Permissions and Reprints

Zusammenfassung

Kardiovaskuläre Erkrankungen und Tumorerkrankungen stellen nach wie vor weltweit die führenden Ursachen für Morbidität und Mortalität dar [1]. Durch die niedrig dosierte Gabe von ASS bei Patienten mit okklusiven kardiovaskulären Erkrankungen wie Koronare Herzerkrankung (KHK), periphere arterielle Verschlusskrankheit (pAVK) oder Schlaganfall, können ca. 20 % der thrombotischen vaskulären Komplikationen verhindert werden [2]. Insbesondere in der kardiovaskulären Sekundärprävention zeigt sich ein günstiges Nutzen-Risikoprofil einer ASS-Dauermedikation. Inwiefern ASS auch in der Primärprävention kardiovaskulärer Erkrankungen indiziert ist, wird derzeit noch kontrovers diskutiert. Ziel dieser Arbeit ist es, eine aktuelle Übersicht über die Evidenz einer niedrig dosierten ASS-Therapie in der Primär- und Sekundärprävention kardiovaskulärer Erkrankungen zu geben und darüber hinaus den möglichen zusätzlichen Nutzen einer ASS-Therapie in der Prävention von Tumoren zu diskutieren

Abstract

Cardiovascular disease and cancer are the leading causes of morbidity and mortality worldwide. Low-dose ASA has been shown to effectively prevent about one fifth of atherothrombotic vascular complications in patients with previous myocardial infarction, peripheral arterial occlusive disease (PAOD), or stroke [2]. In secondary prevention, the benefits of antiplatelet therapy substantially exceed its risk [2]. By contrast, recommendations for the use of ASA in primary prevention are still a matter of controversy. The aim of this article is to review the current evidence for the efficacy of low-dose ASA in primary and secondary prevention of cardiovascular diseases as well as to discuss its potential additional chemopreventive action.

^* Veronika Sanin und Vanessa Pfetsch teilen sich die Erstautorenschaft.

• Literatur

• 1 WHO. Cardiovascular diseases (CVDs). Fact sheet No 317. www.who.int/mediacentre/factsheets/fs317/en/ Letzter Zugriff: 19.01.2016
  PubMed
• 2 Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. Eur Heart J 2013; 34: 3403-3411
  CrossrefPubMedGoogle Scholar
• 3 Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 2015; 66: 74-85
  CrossrefPubMedGoogle Scholar
• 4 Fischbach W, Darius M, Gross M et al. Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK). Z Gastroenterol 2010; 48: 1156-1163
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-49
  CrossrefPubMedGoogle Scholar
• 6 Patrono C, García Rodríguez LA, Landolfi R et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383
  CrossrefPubMedGoogle Scholar
• 7 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
  CrossrefPubMedGoogle Scholar
• 8 Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216
  CrossrefPubMedGoogle Scholar
• 9 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
  CrossrefPubMedGoogle Scholar
• 10 Huang ES, Strate LL, Ho WW et al. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426-433
  CrossrefPubMedGoogle Scholar
• 11 Ridker PM, Cook NR, Lee IM. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304
  CrossrefPubMedGoogle Scholar
• 12 Berger JS, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313
  CrossrefPubMedGoogle Scholar
• 13 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-2886
  CrossrefPubMedGoogle Scholar
• 14 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701
  CrossrefPubMedGoogle Scholar
• 15 Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i
  PubMedGoogle Scholar
• 16 Colwell JA, Halushka PV, Sarji K et al. Altered platelet function in diabetes mellitus. Diabetes 1976; 25: 826-831
  PubMedGoogle Scholar
• 17 De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531
  CrossrefPubMedGoogle Scholar
• 18 Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-410
  CrossrefPubMedGoogle Scholar
• 19 Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008; 5: 138-144
  CrossrefPubMedGoogle Scholar
• 20 Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; e637S-68S
  PubMedGoogle Scholar
• 21 Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932
  CrossrefPubMedGoogle Scholar
• 22 Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701
  CrossrefPubMedGoogle Scholar
• 23 Stegeman I, Bossuyt PM, Yu T et al. Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis. PLoS one 2015; 10: e0127194
  CrossrefPubMedGoogle Scholar
• 24 Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612
  CrossrefPubMedGoogle Scholar
• 25 Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266
  CrossrefPubMedGoogle Scholar
• 26 Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
  CrossrefPubMedGoogle Scholar
• 27 Cuzick J, Thorat MA, Bosetti C et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57
  CrossrefPubMedGoogle Scholar
• 28 Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613
  CrossrefPubMedGoogle Scholar
• 29 Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615
  CrossrefPubMedGoogle Scholar
• 30 Fraser DM, Sullivan FM, Thompson AM et al. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 2014; 111: 623-627
  CrossrefPubMedGoogle Scholar
• 31 Trabert B, Ness RB, Lo-Ciganic WH et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014; 106: djt431
  CrossrefPubMedGoogle Scholar
• 32 Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 2002; 94: 252-266
  CrossrefPubMedGoogle Scholar
• 33 Sahin IH, Garrett C. Aspirin, PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2013; 368: 289
  CrossrefPubMedGoogle Scholar
• 34 Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4569
  PubMedGoogle Scholar
• 35 Patrono C. Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity. Clin Exp Rheumatol 2001; 19: S45-50
  PubMedGoogle Scholar
• 36 Ruffin 4th MT, Krishnan K, Rock CL et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997; 89: 1152-1160
  CrossrefPubMedGoogle Scholar
• 37 Opie LH, Lopaschuk GD. What is good for the circulation also lessens cancer risk. Eur Heart J 2015; 36: 1157-1162
  CrossrefPubMedGoogle Scholar
• 38 Errico A. Prevention: Daily aspirin and chemoprevention. Nat Rev Clin Oncol 2014; 11 (4) 180-180
  PubMedGoogle Scholar
• 39 Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9: 259-267
  CrossrefPubMedGoogle Scholar
• 40 Andreotti HalvorsenS, ten Berg JM et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014; 64: 319-327
  CrossrefPubMedGoogle Scholar
• 41 Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 235-246
  CrossrefPubMedGoogle Scholar
• 42 US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404
  CrossrefPubMedGoogle Scholar
• 43 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline „Helicobacter pylori and gastroduodenal ulcer disease“ of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230-1263
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-2473
  CrossrefPubMedGoogle Scholar
• 45 Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol 2013; 61: 250-257
  CrossrefPubMedGoogle Scholar
• 46 US Preventive Services Task Force. Draft recommendation statement: Aspirin to prevent cardiovascular disease and cancer. http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-to-prevent-cardiovascular-disease-and-cancer Letzter Zugriff: 04.02.2016
  PubMed